List of Lyvispah drug patents

Lyvispah is owned by Amneal.

Lyvispah contains Baclofen.

Lyvispah has a total of 2 drug patents out of which 0 drug patents have expired.

Lyvispah was authorised for market use on 22 November, 2021.

Lyvispah is available in granules;oral dosage forms.

Lyvispah can be used as treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity; treatment of spasticity resulting from spinal cord injuries and other spinal cord diseases, method for treating spasticity.

The generics of Lyvispah are possible to be released after 29 September, 2041.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792262 AMNEAL Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
Jul, 2039

(16 years from now)

US11491125 AMNEAL Baclofen formulations and methods of minimizing patient exposure to metabolite variations
Sep, 2041

(18 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 22 November, 2021

Treatment: Method for treating spasticity; Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity; Treatment o...

Dosage: GRANULES;ORAL

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in